Page 431 - Binder2

What happens when the next generation of biologics—
personalized, shelf-stable, orally delivered—doesn’t fit the
current pharmacy model at all?

As plant-based, AI-optimized therapies become more
prevalent, the role of the pharmacy is not eliminated—but
transformed. In the world of edible biologics, the
pharmacy becomes less about dispensing and more about
curating, interpreting, and connecting.

Pharmacy as Distribution Center: A Model in
Decline

Today’s biologics require an elaborate infrastructure:

• Manufactured in centralized GMP facilities.
• Shipped via temperature-controlled supply chains.
• Routed through specialty pharmacies that track
dispensing, coverage, and compliance.
• Picked up or delivered with layers of administrative
and financial friction.

This system creates:

• High margins for intermediaries.
• Delays and access barriers for patients.
• Gaps in care, especially for rural, low-income, or
non-English-speaking populations.

Edible biologics dismantle much of this.

Once stabilized through freeze-drying or encapsulation,
these therapies can be:

429